Alteon, Inc.
Phase II trial of Alagebrium initiated in erectile dysfunction
Published in Medical Verdicts and Law Weekly, February 17th, 2005
EMERALD (Evaluation of Alagebrium in Erectile Dysfunction in Diabetic Males on PDE5 Inhibitors) will assess the ability of alagebrium to restore erectile function in diabetic patients with moderate to severe ED who achieve limited benefit from current treatment with phosphodiesterase type 5 (PDE5) inhibitors, the first class of orally active compounds approved for the treatment of ED.
Alagebrium has demonstrated an ability to reverse ED in a preclinical model...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- Aastrom Biosciences, Inc.
Patent expands coverage for single-pass perfusion technology - AmerisourceBergen Corporation
Pharmaceutical firm reports earnings of $0.66 per share - BioDiscovery, Inc.
IT company granted its 6th U.S. patent for microarray image analysis - Brown University
Immunogenic consensus T helper epitopes for HIV vaccine engineered - Business Update
Information-services company implements series of strategic initiatives - CBR Institute Biomedical Research
Cross-clade CD8 response to HIV-IIIB and Chinese B' and C/B' viruses reported - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
